All In Biotech

Drug Trial Radar · NCT06464510

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis: An Open-label, Multicenter, Randomized, Controlled Trial: NoVa

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,800

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Hospital do CoracaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Brazilian Research In Intensive Care Network; National Institute of Science and Technology (INCT) in Precision Intensive Care Medicine
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.

Conditions

  • Septic Shock

Interventions

  • Early VasopressinDrug

    Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.

  • Norepinephrine and Vasopressin for RescueDrug

    Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality or renal replacement therapyTime frame: 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Geral de Caxias do Sul

    Caxias do Sul, Rio Grande do Sul, Brazil · Recruiting

  • Hospital SEPACO

    São Paulo, S, Brazil · Not yet recruiting

  • Hospital Nereu Ramos

    Florianópolis, Santa Catarina, Brazil · Recruiting

  • Hospital de Amor - Unidade Barretos (Fundação PIO XII)

    Barretos, São Paulo, Brazil · Not yet recruiting

  • Hospital do Coracao

    São Paulo, São Paulo, Brazil · Recruiting

  • BP-A Beneficiência Portuguesa de São Paulo

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Hospital São Paulo - UNIFESP

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.